Search hospitals > California > Downey
Kaiser Permanente Downey Medical Center
Claim this profileDowney, California 90242
Global Leader in Uterine Tumors
Global Leader in Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Lymphoma
Conducts research for Relapse
126 reported clinical trials
4 medical researchers
Summary
Kaiser Permanente Downey Medical Center is a medical facility located in Downey, California. This center is recognized for care of Uterine Tumors, Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lymphoma, Relapse and other specialties. Kaiser Permanente Downey Medical Center is involved with conducting 126 clinical trials across 294 conditions. There are 4 research doctors associated with this hospital, such as Robert M. Cooper, Lisa A. Mueller, Hung N. Tran, and Neha G. Vaghasia.Area of expertise
1Uterine Tumors
Global LeaderStage IV
Stage I
Stage II
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Robert M. CooperKaiser Permanente Downey Medical Center7 years of reported clinical research
Expert in Uterine Tumors
Expert in Neuroblastoma
49 reported clinical trials
95 drugs studied
Lisa A. MuellerKaiser Permanente Downey Medical Center7 years of reported clinical research
Studies Cancer
Studies Uterine Tumors
5 reported clinical trials
8 drugs studied
Hung N. TranKaiser Permanente Downey Medical Center5 years of reported clinical research
Studies Cerebral Gliomas
Studies Fibrillary Astrocytoma
4 reported clinical trials
12 drugs studied
Neha G. VaghasiaKaiser Permanente Downey Medical Center4 years of reported clinical research
Studies Desmoid Tumor
Studies Fibroid
3 reported clinical trials
13 drugs studied
Clinical Trials running at Kaiser Permanente Downey Medical Center
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Testicular cancer
T-Lymphoblastic Leukemia/Lymphoma
Acute Leukemia
Leukemia
Uterine Tumors
Germ Cell Tumors
Ovarian Tumors
Ovarian Choriocarcinoma
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kaiser Permanente Downey Medical Center?
Kaiser Permanente Downey Medical Center is a medical facility located in Downey, California. This center is recognized for care of Uterine Tumors, Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lymphoma, Relapse and other specialties. Kaiser Permanente Downey Medical Center is involved with conducting 126 clinical trials across 294 conditions. There are 4 research doctors associated with this hospital, such as Robert M. Cooper, Lisa A. Mueller, Hung N. Tran, and Neha G. Vaghasia.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.